Cervical carcinomas (CC) arise in large part due to infection with human papillomaviruses (HPV), with persistence of viral oncogenic proteins E6 and E7 in most if not all CC. These proteins serve as a source of “foreign” antigens, generating a strong rationale for immunotherapeutic approaches. A number of approaches including cancer vaccines, adoptive cell therapy, and immune checkpoint blockade have been explored in cervical cancer and in pre-cancerous lesions, each demonstrating an ability to induce deep and durable responses, though benefits have been limited to a minority of patients to date. Herein we summarize the results of these studies, discuss ongoing combination trials, and provide perspectives for future of immunotherapy in cervical cancer.